Author of the publication

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

, , , , , , , , , , , , and . Blood, 104 (3): 634–641 (2004)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, , , , , , , , , and 3 other author(s). Blood, 104 (3): 634–641 (2004)Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone), , , , , , , , , and 2 other author(s). Annals of hematology, 87 (9): 717–726 (2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), , , , , , , , , and 16 other author(s). The Lancet Oncology, 9 (2): 105–116 (2008)The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL, , , , , , , , , and 5 other author(s). Blood, 119 (14): 3276–3284 (2012)Ein kollaboratives Informationssystem für das Klinische Studienzentrum am Klinikum der Universität zu Köln, , , , , , , , and . Posterpräsentation auf dem Kongress Medizin und Gesellschaft 2007, Augsburg, (2007)